G1 Therapeutics, Inc. (GTHX)
NASDAQ: GTHX · IEX Real-Time Price · USD
3.910
-0.040 (-1.01%)
Jul 26, 2024, 4:00 PM EDT - Market closed
G1 Therapeutics Revenue
G1 Therapeutics had revenue of $14.48M in the quarter ending March 31, 2024, with 11.82% growth. This brings the company's revenue in the last twelve months to $84.04M, up 46.55% year-over-year. In the year 2023, G1 Therapeutics had annual revenue of $82.51M with 60.84% growth.
Revenue (ttm)
$84.04M
Revenue Growth
+46.55%
P/S Ratio
2.43
Revenue / Employee
$840,410
Employees
100
Market Cap
204.42M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionGTHX News
- 1 day ago - G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 - GlobeNewsWire
- 25 days ago - G1 Therapeutics Added to the Russell 2000® and 3000® Indexes - GlobeNewsWire
- 4 weeks ago - Why Is Cancer-Focused G1 Therapeutics Stock Trading Lower On Monday? - Benzinga
- 4 weeks ago - G1 Therapeutics' breast cancer drug fails in late-stage trial - Reuters
- 4 weeks ago - G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC) - GlobeNewsWire
- 7 weeks ago - G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) - GlobeNewsWire
- 2 months ago - G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting - GlobeNewsWire